Formulation and Optimization of Monolithic Fixed-Dose Combination of Metformin HCl and Glibenclamide Orodispersible Tablets

Table 6

Effects of independent variables on friability, disintegration time, and percentage of drug release in the first 30 minutes (mean ± SD).

Formulation code	Friability (%)	Disintegration time (seconds)	DR (%) in 30 min
			MET	GLB
Fp1	1.05 ± 0.26	45 ± 0.73	91.87 ± 1.31	89.72 ± 1.81
Fp2	0.73 ± 0.03	68 ± 1.07	92.05 ± 1.02	90.85 ± 1.32
Fp3	1.12 ± 0.35	13 ± 0.78	89.40 ± 2.14	91.18 ± 0.95
Fp4	0.80 ± 0.02	37 ± 1.78	95.33 ± 0.98	85.30 ± 1.14
Fp5	0.50 ± 0.05	76 ± 1.07	89.25 ± 1.23	86.96 ± 2.10
Fp6	0.23 ± 0.01	83 ± 0.89	94.26 ± 1.64	84.30 ± 1.81
Fp7	0.99 ± 0.26	28 ± 0.63	91.59 ± 0.67	89.36 ± 0.86
Fp8	0.30 ± 0.10	45 ± 0.73	93.32 ± 1.59	86.31 ± 1.91

DR (%) = percentage of drug release.